This article was originally published in The Gray Sheet
BIOSOLVE-1 trial evaluating the firm's Drug-Eluting Absorbable Metal Scaffold in patients with de novo coronary artery lesions is under way, with the first implant occurring July 27, Biotronik reports. The first-of-its kind scaffold, made with biodegradeable magnesium, combines the advantages of a drug-eluting stent and a reliable degradation profile that allows the vessel to return slowly to its natural physiology, according to the company. The device may be a safer option than drug-eluting stents, which remain in the body and have potential complications like late stent thrombosis, Biotronik suggests
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.